Trial Condition(s):

N/A

BAY 43 9006 in combination with doxorubicin chemotherapy in patients

Bayer Identifier:

10916

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Primary objective: To define the safety profile of continuously administered
sorafenib in combination with 3-weekly administrations of doxorubicin in subjects with advanced, refractory solid tumors;
Secondary objectives were
• To evaluate the pharmacokinetics and pharmacodynamics of sorafenib in combination with doxorubicin and vice versa;
• To determine the objective tumor response rate including complete and partial response rates based on WHO criteria.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
54
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

For details, please refer to trial results

Additional Information